|
|
Pt w/ extensive bone and liver mets, PSA 50 ng/mL, minimal complaints of pain (PS = 0)?Pt w/ extensive bone and liver mets, PSA 50 ng/mL, minimal complaints of pain (PS = 0)?A 62-year-old man with a good performance status (PS = 0) presents de novo with a PSA of 50 ng/mL and extensive bone and liver metastases but has only minimal complaints of pain. What systemic treatment approach would you generally recommend, and what bone-targeted treatment, if any, would you recommend at this time? How would you care for the same patient if he were 80 years old? Gravis G et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149-58. Abstract Lu-Yao GL et al. 15-year survival outcomes following primary androgen deprivation therapy for localized prostate cancer. Proc ASCO 2014;Abstract 5033. Parker C et al. Impact of node status and radiotherapy on failure-free survival in patients with newly diagnosed non-metastatic prostate cancer: Data from >690 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Proc ESMO 2014;Abstract 754O. STAMPEDE: Systemic therapy in advancing or metastatic prostate cancer: Evaluation of drug efficacy: A multi-stage multi-arm randomized controlled trial. NCT00268476 Sweeney C et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. Proc ASCO 2014;Abstract LBA2. Voskoboynik M et al. 'Charting a new course for prostate cancer' — Currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1253-6. Abstract |